Clinical Trial Update: Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and tolerability of multiple-dose regimens of CHF 5074 in Alzheimer's disease has completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• CHF 5074

Snippet

Sponsor: CERESPIR | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2016-01-11